Guide · Updated November 2026

Zepbound for sleep apnea: a different insurance path

Zepbound has two separate FDA approvals: weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity. In Medicaid and Medicare Part D, the rules that let programs exclude weight-loss drugs do not reach the second one, because it isn't a weight-loss use. Here's how the two coverage paths actually differ.

This explains a coverage mechanism, not a guarantee your plan covers this drug. Ask your insurer for its written policy before assuming any of this applies to you.

The two Zepbound approvals, at a glance

Why the indication changes the rule

Medicaid’s authority to exclude these drugs comes from one line in federal law, Section 1927(d)(2) of the Social Security Act, which lets states exclude or restrict “agents when used for anorexia, weight loss, or weight gain.” States that use this carve-out are excluding the drug because of what it’s being used for, not because of what the drug is. The exclusion doesn’t apply to a prescription written for a different, FDA-approved use.

Obstructive sleep apnea is that different use. When a Zepbound prescription is written and documented for moderate-to-severe OSA rather than weight management, it falls outside the statutory language that lets a state Medicaid program decline to cover it. That doesn’t make coverage automatic. Regular Medicaid rules, like prior authorization, formulary placement, and documentation requirements, still apply. It just means the state can’t point to the weight-loss carve-out as the reason to deny it.

The same logic shows up on the Medicare side, though through a different mechanism. Medicare Part D has historically excluded drugs used for weight loss. A Zepbound prescription written and documented for OSA isn’t a weight-loss prescription under that framework, so it can be evaluated under Part D’s normal coverage rules for treating a diagnosed condition, the same way any other covered drug would be. This is separate from the Medicare GLP-1 Bridge program, a different, temporary mechanism built for weight management. Medicare.gov says people with moderate-to-severe sleep apnea are not eligible for the Bridge and that their Part D plan might cover GLP-1s for that condition.

What the approval was based on

The FDA’s OSA approval rests on the SURMOUNT-OSA trial, which enrolled adults with obesity and an apnea-hypopnea index (AHI) of at least 15 events per hour, split into a group not using positive airway pressure (PAP) therapy and a group already using it. Over 52 weeks, the Zepbound label reports AHI falling by 25.3 events per hour in the non-PAP group and 29.3 events per hour in the PAP group, compared with about 5 events per hour on placebo in each. This is a sleep-severity measure tied to the OSA indication, not a weight-loss result, and individual outcomes vary. Talk to your sleep specialist about whether you meet the trial’s severity criteria before assuming you qualify.

Medicare: two different paths, don’t mix them up

If your Zepbound prescription is for weight management, your realistic Medicare paths are the temporary GLP-1 Bridge program (a $50 monthly copay through December 31, 2027, with prior authorization and BMI criteria, covering the Zepbound KwikPen but not the single-dose pen or vial) or paying cash, since standard Part D excludes the weight-loss use. Our Medicare coverage guide and copay card comparison cover that path in detail.

If your prescription is for OSA, that’s not the Bridge program. It’s ordinary Part D coverage for a diagnosed medical condition, subject to your plan’s formulary tier, prior authorization requirements, and standard 2026 cost-sharing: a $615 deductible and a $2,100 annual out-of-pocket threshold under the standard benefit design, after which you owe nothing more for covered drugs that year. What you actually pay per fill before hitting that cap depends on your plan’s formulary tier for Zepbound, which varies the same way it does for any other covered drug. Ask your Part D plan directly what tier Zepbound sits on and what your copay or coinsurance is for the OSA indication, since a representative may default to describing the weight-management exclusion if you don’t name the diagnosis on the call.

Medicaid: check your state, and check the diagnosis coding

Covering GLP-1s for weight management is optional for state Medicaid programs under the federal carve-out, and many states do not cover it. The OSA indication sits outside that carve-out, so a state that excludes Zepbound for weight loss may still be required to evaluate it for OSA the way it would any other FDA-approved treatment for a covered condition, subject to the state’s own prior authorization and documentation rules. This varies by state and by managed-care plan within a state. Ask your state Medicaid program or managed-care plan how it handles the OSA indication rather than assuming the weight-loss answer applies.

Getting the diagnosis coding right matters here more than almost anywhere else in GLP-1 coverage. A prior authorization request coded for obesity or weight management, even if OSA is mentioned in the chart, can be evaluated under the weight-loss exclusion. A request that documents the OSA diagnosis, the qualifying AHI, and the sleep specialist’s findings as the primary basis for the prescription is the one that has a path around that carve-out.

Commercial insurance: plan design still varies

Commercial plans aren’t bound by the Medicaid statute or Medicare’s Part D framework, so this legal mechanism doesn’t apply to them the same way. Many commercial plans do treat OSA and weight-management indications differently in their own coverage policies, since Zepbound is the only GLP-1 among Wegovy, Zepbound and Foundayo whose label includes OSA, so there’s no formulary alternative in that group carrying the same approved use. But a commercial plan can still choose to exclude weight-loss drugs broadly and separately restrict or require step therapy for the OSA indication under its own policy. Check your plan’s coverage policy for the OSA indication rather than assuming the reasoning above applies to an employer-sponsored plan the same way it applies to Medicaid or Medicare.

Bottom line

Zepbound’s sleep apnea approval is a separate FDA indication from its weight-management approval, and that distinction matters most for Medicaid and Medicare Part D, where the “weight loss” exclusion doesn’t reach a prescription written for OSA. That’s a real coverage opening, not a guarantee: your documentation has to reflect the OSA diagnosis and severity criteria, and your plan still applies its own prior authorization and formulary rules. If you have moderate-to-severe sleep apnea and obesity, ask your sleep specialist whether you meet the trial’s eligibility criteria and whether coding the prescription for OSA changes what your plan will cover.

FAQ

Does Medicare cover Zepbound for sleep apnea?

Medicare Part D can cover Zepbound when it’s prescribed and documented for moderate-to-severe obstructive sleep apnea, since that’s a separate FDA-approved indication from weight loss. Coverage still depends on your plan’s formulary and prior authorization rules. People with moderate-to-severe OSA are not eligible for the Medicare GLP-1 Bridge, so the Part D plan is the route.

Is Zepbound for sleep apnea covered differently than Zepbound for weight loss?

Yes. Weight-management use is subject to Medicaid’s optional weight-loss exclusion and, on Medicare, generally requires the separate GLP-1 Bridge program or cash pay. The OSA indication isn’t weight loss under those rules, so it can be evaluated under each program’s ordinary coverage process instead.

Does Medicaid cover Zepbound for sleep apnea?

It depends on your state and plan, but the federal carve-out that lets states exclude weight-loss drugs doesn’t apply to the OSA indication, since it’s a different FDA-approved use. Ordinary Medicaid coverage, prior authorization, and documentation rules still apply, so ask your state program directly.

What AHI level do I need to qualify for Zepbound’s sleep apnea indication?

The trial supporting FDA approval enrolled adults with obesity and an apnea-hypopnea index of at least 15 events per hour. Whether you meet the clinical criteria for this indication is a decision for your sleep specialist based on your own sleep study results.

Will my insurer know I mean the sleep apnea indication, not weight loss?

Not necessarily. Make sure the prior authorization request documents the OSA diagnosis, your AHI, and your sleep specialist’s findings as the basis for the prescription. A request that only lists a weight-related diagnosis code can be evaluated under the weight-loss exclusion even if OSA is mentioned elsewhere in the chart.

Related

Guides:

• GLP-1 BMI Eligibility Chart
• GLP-1 Medicare Coverage 2026
• Does Medicaid Cover GLP-1?
• GLP-1 Prior Authorization: Requirements, Documentation, Timeline
• How to Get Insurance to Cover GLP-1 Medications

Tools: Insurance Coverage Checker

Compare: All Providers

What we checked

This AI-assisted public-source desk check reviewed the FDA’s December 2024 OSA approval announcement, the Zepbound prescribing information, Section 1927 of the Social Security Act, Medicare.gov’s GLP-1 Bridge page, and CMS’s 2026 Part D program instructions on November 4, 2026. This explains a coverage mechanism, not a guarantee your plan covers this drug. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.